Table 3.
Preclinical transgenic models used to study human cancers caused by MCPyV.
| Virus | Protein expression | Cell type/tissue targeted | Other genes/cofactors used in model | Disease development and anatomical site | References |
|---|---|---|---|---|---|
| MCPyV MCC350 isolate | ST | K5+ basal cells in pre-term embryos | None | Skin: Proliferation, hyperplasia, dysplastic epithelium | [293] |
| MCPyV MCC350 isolate | ST | Conditional (K5+ cells; induced in postnatal animals) | None | Skin: Carcinoma in situ | [293] |
| MCPyV codon-optimized | ST | Conditional (inducible ubiquitous expression and Atoh1+ cells) | Conditional p53 deletion | Liver, spleen tumors with ubiquitous expression; Merkel cell proliferation with Atoh1-specific expression | [296] |
| MCPyV MCCw168 isolate | tLT | K5+ basal cells | None | None | [295] |
| MCPyV MCCw168 isolate | Early region; tLT + ST | Conditional (constitutive expression in K14+ cells) | None | Skin: hyperplasia, proliferation, E2F-dependent gene expression, spontaneous tumor development | [298] |
| MCPyV MCC350 isolate | ST | K5+ basal cells | Atoh1 | Skin: intraepidermal MCC-like tumors | [295] |
| MCPyV MCCw168 isolate | tLT | K5+ basal cells | Atoh1 | Skin: ectopic Merkel cells (effect of Atoh1 expression) | [295] |
| MCPyV MCCw168 and MCC350 isolates | tLT + ST | K5+ basal cells | Atoh1 + conditional p53 deletion | Skin: MCC development | [303] |